In brain cancers where BRG1 has a crucial role in tumour cell progression such as SHH-group MB and GBM, synthetic lethality is not a feasible strategy as BRG1 retains its function in the wild-type form. This evidence concerns the gene SMARCA4 and glioblastoma.